FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213279348> ?p ?o ?g. }

• W4213279348 abstract "Background The reduction of lung inflammation is one of the goals of cystic fibrosis therapy. Inhaled corticosteroids are often used in this respect to treat children and adults with cystic fibrosis. The rationale for this is their potential to reduce lung damage arising from inflammation, as well as their effect on symptomatic wheezing. It is important to establish the current level of evidence for the risks and benefits of inhaled corticosteroids, especially in the light of their known adverse effects on growth. This is an update of a previously published review; however, due to the lack of research in this area, we do not envisage undertaking any further updates. Objectives To assess the effectiveness of taking regular inhaled corticosteroids compared to not taking them in children and adults with cystic fibrosis. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We requested information from pharmaceutical companies manufacturing inhaled corticosteroids and authors of identified trials. Date of most recent search of the Group's Trials Register: 19 November 2018. Selection criteria Randomised or quasi‐randomised trials, published and unpublished, comparing inhaled corticosteroids to placebo or standard treatment in individuals with cystic fibrosis. Data collection and analysis Two independent authors assessed methodological quality and risk of bias in trials using established criteria and extracted data using standard pro formas. The quality of the evidence was assessed using the GRADE criteria. Main results The searches identified 35 citations, of which 27 (representing 13 trials) were eligible for inclusion. These 13 trials reported the use of inhaled corticosteroids in 525 people with cystic fibrosis aged between 6 and 55 years. One was a withdrawal trial in 171 individuals who were already taking inhaled corticosteroids. Methodological quality and risk of bias were difficult to assess from published information. Objective measures of airway function were reported in most trials but were often incomplete and reported at different time points. We found no difference in forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) % predicted in any of the trials, although the quality of the evidence was low due to risks of bias within the included trials and low participant numbers. We are uncertain whether inhaled corticosteroids result in an improvement in exercise tolerance, bronchial hyperreactivity or exacerbations as the quality of the evidence was very low. Data from one trial suggested that inhaled corticosteroids may make little or no difference to quality of life (low‐quality evidence). Three trials reported adverse effects, but the quality of the evidence is low and so we are uncertain whether inhaled corticosteroids increase the risk of adverse effects. However, one study did show that growth was adversely affected by high doses of inhaled corticosteroids. Authors' conclusions Evidence from these trials is of low to very low quality and insufficient to establish whether inhaled corticosteroids are beneficial in cystic fibrosis, but withdrawal in those already taking them has been shown to be safe. There is some evidence they may cause harm in terms of growth. It has not been established whether long‐term use is beneficial in reducing lung inflammation, which should improve survival, but it is unlikely this will be proven conclusively in a randomised controlled trial." @default.
• W4213279348 created "2022-02-24" @default.
• W4213279348 creator A5054590049 @default.
• W4213279348 creator A5071649721 @default.
• W4213279348 creator A5083738129 @default.
• W4213279348 date "2019-07-04" @default.
• W4213279348 modified "2023-09-28" @default.
• W4213279348 title "Inhaled corticosteroids for cystic fibrosis" @default.
• W4213279348 cites W1533405076 @default.
• W4213279348 cites W1582446248 @default.
• W4213279348 cites W159304422 @default.
• W4213279348 cites W1741300860 @default.
• W4213279348 cites W1850996803 @default.
• W4213279348 cites W1963763550 @default.
• W4213279348 cites W1963961254 @default.
• W4213279348 cites W1972355263 @default.
• W4213279348 cites W1975022088 @default.
• W4213279348 cites W1975096143 @default.
• W4213279348 cites W1975959231 @default.
• W4213279348 cites W1978132663 @default.
• W4213279348 cites W1980017808 @default.
• W4213279348 cites W1982291590 @default.
• W4213279348 cites W1988348875 @default.
• W4213279348 cites W1989694167 @default.
• W4213279348 cites W2004907878 @default.
• W4213279348 cites W2018403515 @default.
• W4213279348 cites W20194251 @default.
• W4213279348 cites W2020716977 @default.
• W4213279348 cites W2025220428 @default.
• W4213279348 cites W2033877785 @default.
• W4213279348 cites W2034625444 @default.
• W4213279348 cites W2034954976 @default.
• W4213279348 cites W2044847259 @default.
• W4213279348 cites W2051022650 @default.
• W4213279348 cites W2057119680 @default.
• W4213279348 cites W2058527527 @default.
• W4213279348 cites W2061278890 @default.
• W4213279348 cites W2070097998 @default.
• W4213279348 cites W2075581277 @default.
• W4213279348 cites W2078078890 @default.
• W4213279348 cites W2079983153 @default.
• W4213279348 cites W2081002142 @default.
• W4213279348 cites W2082466693 @default.
• W4213279348 cites W2087560613 @default.
• W4213279348 cites W2093174178 @default.
• W4213279348 cites W2096443988 @default.
• W4213279348 cites W2107656210 @default.
• W4213279348 cites W2107673468 @default.
• W4213279348 cites W2108043979 @default.
• W4213279348 cites W2109454767 @default.
• W4213279348 cites W2115261152 @default.
• W4213279348 cites W2121399207 @default.
• W4213279348 cites W2124135806 @default.
• W4213279348 cites W2124212409 @default.
• W4213279348 cites W2125435699 @default.
• W4213279348 cites W2127868905 @default.
• W4213279348 cites W2130235475 @default.
• W4213279348 cites W2131874834 @default.
• W4213279348 cites W2142180792 @default.
• W4213279348 cites W2150817537 @default.
• W4213279348 cites W2159638894 @default.
• W4213279348 cites W2160220254 @default.
• W4213279348 cites W2162672497 @default.
• W4213279348 cites W2164362953 @default.
• W4213279348 cites W2169843278 @default.
• W4213279348 cites W2471349741 @default.
• W4213279348 cites W2769186313 @default.
• W4213279348 cites W4210997330 @default.
• W4213279348 cites W4211067424 @default.
• W4213279348 cites W4211167906 @default.
• W4213279348 cites W4213342930 @default.
• W4213279348 cites W4242410317 @default.
• W4213279348 cites W4250517990 @default.
• W4213279348 cites W4251717373 @default.
• W4213279348 cites W4291674955 @default.
• W4213279348 doi "https://doi.org/10.1002/14651858.cd001915.pub6" @default.
• W4213279348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31271656" @default.
• W4213279348 hasPublicationYear "2019" @default.
• W4213279348 type Work @default.
• W4213279348 citedByCount "10" @default.
• W4213279348 countsByYear W42132793482020 @default.
• W4213279348 countsByYear W42132793482021 @default.
• W4213279348 countsByYear W42132793482022 @default.
• W4213279348 crossrefType "journal-article" @default.
• W4213279348 hasAuthorship W4213279348A5054590049 @default.
• W4213279348 hasAuthorship W4213279348A5071649721 @default.
• W4213279348 hasAuthorship W4213279348A5083738129 @default.
• W4213279348 hasBestOaLocation W42132793482 @default.
• W4213279348 hasConcept C126322002 @default.
• W4213279348 hasConcept C142724271 @default.
• W4213279348 hasConcept C168563851 @default.
• W4213279348 hasConcept C17744445 @default.
• W4213279348 hasConcept C177713679 @default.
• W4213279348 hasConcept C1862650 @default.
• W4213279348 hasConcept C187212893 @default.
• W4213279348 hasConcept C197934379 @default.
• W4213279348 hasConcept C199539241 @default.
• W4213279348 hasConcept C204787440 @default.
• W4213279348 hasConcept C27081682 @default.
• W4213279348 hasConcept C2776938444 @default.

• next